Designs, develops, and manufactures hearing instruments for adults and children. Produces and distributes cochlear implants for individuals with severe hearing loss. Now — the numbers.
This is an established company with proven profits.
No real growth (2% a year).
The gap is $1.2B. In times of high interest rates, a gap like that can squeeze a company.
The market pays 30.5× for every dollar of annual profit — around what a business like this usually costs.
No analyst target is on record for this company.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are growing slowly.
The stock trades 38% below its peak. The market has trimmed its expectations for the company.
Our checks did not surface a specific strength to highlight here.
Over the last 4 years, sales grew only 2% a year on average. At this size, speeding back up is not easy.
Getting in and out without moving the price could prove difficult. Council score: 2/10.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the revenue breakdown.